Laurain, A. http://orcid.org/0000-0002-9806-7953
Bouchard, D.
Rouillon, J.-M.
Petit, P.
Liddo, A.
Vinson Bonnet, B.
Venara, A.
Didelot, J.-M.
Bonnaud, G.
Senéjoux, A.
Higuero, T.
Delasalle, P.
Tarrerias, A.-L.
Devulder, F.
Castinel, A.
Thomas, C.
Pillant Le Moult, H.
Favreau-Weltzer, C.
Abramowitz, L.
Clinical trials referenced in this document:
Documents that mention this clinical trial
French multicentre prospective evaluation of radiofrequency ablation in the management of haemorrhoidal disease
https://doi.org/10.1007/s10151-023-02787-1
Funding for this research was provided by:
Ramsay Santé
Article History
Received: 12 December 2022
Accepted: 14 March 2023
First Online: 2 April 2023
Declarations
:
: Abramowitz Laurent, Laurain Anne and Dominique Bouchard are consultants for F Care. Aurelien Venara is consultant for Intuitive surgery, Sanofi Aventis, Takeda, Thermofisher. Guillaume Bonnaud is consultant for Abbvie, Alfasigma, Bouchara Recordatti, Celltrion, Ferring, Janssen, Gilead, Medtronic, MSD, Norgine, PFIZER, Roche, Takeda, Tillotts. The other authors declare that they have no conflict of interest.
: The study protocol was validated by the Ile de France Ethics Committee. The MR 001 reference methodology was applied for the CNIL assessment. The protocol design, the analysis of results and the drafting of the article were carried out independently from the study sponsors.
: Written informed consent forms were collected from the patients.